JP2019517508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517508A5 JP2019517508A5 JP2018563076A JP2018563076A JP2019517508A5 JP 2019517508 A5 JP2019517508 A5 JP 2019517508A5 JP 2018563076 A JP2018563076 A JP 2018563076A JP 2018563076 A JP2018563076 A JP 2018563076A JP 2019517508 A5 JP2019517508 A5 JP 2019517508A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pharmaceutical composition
- cell receptor
- medicine
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 63
- 229920001184 polypeptide Polymers 0.000 claims 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims 62
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 53
- 239000008194 pharmaceutical composition Substances 0.000 claims 52
- 108091008874 T cell receptors Proteins 0.000 claims 50
- 239000003814 drug Substances 0.000 claims 45
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 33
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 33
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 31
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 31
- 210000001744 T-lymphocyte Anatomy 0.000 claims 28
- 102000039446 nucleic acids Human genes 0.000 claims 27
- 108020004707 nucleic acids Proteins 0.000 claims 27
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 150000001413 amino acids Chemical class 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 14
- 230000001747 exhibiting effect Effects 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 10
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 238000002255 vaccination Methods 0.000 claims 6
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 5
- 239000012270 PD-1 inhibitor Substances 0.000 claims 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims 4
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 108010017842 Telomerase Proteins 0.000 claims 2
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 claims 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 101710204040 Myosin-3 Proteins 0.000 claims 1
- 229940124060 PD-1 antagonist Drugs 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102000000763 Survivin Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022132995A JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760.7 | 2016-06-02 | ||
| EP16172760 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022132995A Division JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517508A JP2019517508A (ja) | 2019-06-24 |
| JP2019517508A5 true JP2019517508A5 (OSRAM) | 2020-07-16 |
| JP7321709B2 JP7321709B2 (ja) | 2023-08-07 |
Family
ID=56132759
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563076A Active JP7321709B2 (ja) | 2016-06-02 | 2017-06-02 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
| JP2022132995A Pending JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022132995A Pending JP2022171684A (ja) | 2016-06-02 | 2022-08-24 | がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (OSRAM) |
| EP (2) | EP3463436B1 (OSRAM) |
| JP (2) | JP7321709B2 (OSRAM) |
| AU (1) | AU2017275782B2 (OSRAM) |
| CA (1) | CA3026172A1 (OSRAM) |
| DK (1) | DK3463436T3 (OSRAM) |
| ES (1) | ES2965957T3 (OSRAM) |
| FI (1) | FI3463436T3 (OSRAM) |
| HR (1) | HRP20231650T1 (OSRAM) |
| HU (1) | HUE065176T2 (OSRAM) |
| LT (1) | LT3463436T (OSRAM) |
| PL (1) | PL3463436T3 (OSRAM) |
| PT (1) | PT3463436T (OSRAM) |
| RS (1) | RS65007B1 (OSRAM) |
| SI (1) | SI3463436T1 (OSRAM) |
| WO (1) | WO2017207814A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108383894A (zh) | 2010-02-16 | 2018-08-10 | 阿尔特公司 | 多肽及其应用 |
| RS65007B1 (sr) | 2016-06-02 | 2024-01-31 | Ultimovacs Asa | Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kancera |
| GB201803178D0 (en) * | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| TWI805792B (zh) * | 2018-06-29 | 2023-06-21 | 日商大鵬藥品工業股份有限公司 | 抗腫瘤劑及其評估方法 |
| CN117940152A (zh) | 2021-06-09 | 2024-04-26 | 阿尔特有限公司 | 缀合物 |
| WO2024083867A1 (en) * | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Biomarker |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU784062B2 (en) | 1999-08-23 | 2006-01-19 | Dana-Farber Cancer Institute, Inc. | Novel B7-4 molecules and uses therefor |
| PT1234031T (pt) | 1999-11-30 | 2017-06-26 | Mayo Foundation | B7-h1, uma nova molécula imunoregulatória |
| ATE552849T1 (de) * | 2002-04-12 | 2012-04-15 | Medarex Inc | Behandlungsverfahren unter verwendung von ctla-4 antikörpern |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| CN108383894A (zh) | 2010-02-16 | 2018-08-10 | 阿尔特公司 | 多肽及其应用 |
| RS55670B1 (sr) | 2010-03-15 | 2017-06-30 | Academisch Ziekenhuis Leiden | Peptidi, konjugati i metod za povećanje imunogenosti vakcine |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| HK1212237A1 (en) | 2012-08-31 | 2016-06-10 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| SG10201710473VA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
| MX369709B (es) | 2013-03-15 | 2019-11-19 | Univ Pennsylvania | Vacunación mejorada contra tirosinasa. |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| JP2017500313A (ja) | 2013-12-09 | 2017-01-05 | ブレット バイオテクノロジー， インコーポレーテッドＢｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用 |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| US9903102B2 (en) | 2013-12-27 | 2018-02-27 | Xiamen Solex High-Tech Industries Co., Ltd. | Concealed embedded component for a waterway system |
| JP6581101B2 (ja) | 2014-02-14 | 2019-09-25 | イミューン デザイン コーポレイション | 局所免疫刺激及び全身免疫刺激の組み合わせによる癌の免疫療法 |
| US10933106B2 (en) | 2014-02-25 | 2021-03-02 | Deutsches Krebsforschungszentrum | RNA viruses for immunovirotherapy |
| NZ725459A (en) | 2014-05-13 | 2023-04-28 | Bavarian Nordic As | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| DK3142689T3 (da) | 2014-05-13 | 2021-02-15 | Bavarian Nordic As | Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3 |
| US20170136127A1 (en) | 2014-07-01 | 2017-05-18 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| US20170196952A1 (en) | 2014-07-07 | 2017-07-13 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| MX2017000836A (es) | 2014-07-18 | 2017-11-17 | Advaxis Inc | Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| EP3209692B1 (en) | 2014-10-23 | 2024-05-22 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| EP3215182B1 (en) | 2014-11-05 | 2023-01-04 | The Regents of The University of California | Combination immunotherapy |
| PT3405212T (pt) | 2016-01-19 | 2020-08-25 | Pfizer | Vacinas para o cancro |
| RS65007B1 (sr) | 2016-06-02 | 2024-01-31 | Ultimovacs Asa | Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kancera |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517508A5 (OSRAM) | ||
| AU2018250464B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| TWI796299B (zh) | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 | |
| CA2934073A1 (en) | Combination therapy with neoantigen vaccine | |
| EP3666793A3 (en) | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 | |
| JP2021100956A (ja) | インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 | |
| TW202140068A (zh) | 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 | |
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| KR20160044035A (ko) | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 | |
| KR20170045240A (ko) | 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도 | |
| US20170021039A1 (en) | Cancer Therapy | |
| Fisher et al. | Neoadjuvant anti-tumor vaccination prior to surgery enhances survival | |
| Nasonov et al. | The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA | |
| Parums | Status of immune therapy in non-small cell lung cancer (NSCLC) | |
| Myers et al. | Overcoming Cancer Tolerance with Immune Checkpoint Blockade | |
| RU2020117746A (ru) | Иммунотерапевтические способы лечения и/или профилактики рака легких |